The ACE inhibitors cilazapril and captopril were administered at 10 and 100 mg/day, respectively, to spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto rats (WKY) from the 12th to the 22nd week of life. Both drugs produced statistically significant reductions in systolic and diastolic blood pressure, left-ventricular mass and index of left-ventricular hypertrophy in SHR. After cilazapril treatment, the morphology of SHR cardiocytes became similar to that in untreated normotensive rats, while in captopril-treated rats, myofibrils were disarranged, obliquely oriented and smaller than normal, with areas of electron-transparent sarcoplasm separating the myofibril bundles; mitochondria were also altered. In WKY rats, we observed no statistically significant changes in blood pressure, ventricular weight and hypertrophy index between the two drugs; however, there were different effects of the two drugs on the ultrastructural morphology of the myocardium. These observations suggest that these two molecularly dissimilar ACE inhibitors act differently at the tissue level despite similar effects on blood pressure and left-ventricular mass.

Keywords:
Myocardium, Ultrastructure, ACE inhibition, Cilazapril, Captopril
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.